首页> 外文OA文献 >Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

【2h】

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

机译：吉非替尼与贝伐单抗联合作为晚期非小细胞肺癌激活EGFR基因突变的一线治疗的II期临床试验：冈山肺癌研究小组试验1001

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ichihara Eiki; Hotta Katsuyuki; Nogami Naoyuki; Kuyama Shoichi; Kishino Daizo; Fujii Masanori; Kozuki Toshiyuki; Tabata Masahiro; Harada Daijiro; Chikamori Kenichi; Aoe Keisuke; Ueoka Hiroshi; Hosokawa Shinobu; Bessho Akihiro; Hisamoto-Sato Akiko; Kubo Toshio; Oze Isao; Takigawa Nagio; Tanimoto Mitsune; Kiura Katsuyuki;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001 [J] . Ichihara Eiki, Hotta Katsuyuki, Nogami Naoyuki, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第3期

机译：吉非替尼的第二阶段试验与Bevacizumab相结合作为先进非小细胞肺癌的一线治疗，具有激活EGFR基因突变：冈山肺癌研究组试验1001
2. A Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001 [J] . Ichihara Eiki, Hotta Katsuyuki, Nogami Naoyuki, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第3期

机译：吉非替尼与贝伐单抗联合作为晚期非小细胞肺癌激活EGFR基因突变的一线治疗的II期临床试验：冈山肺癌研究小组试验1001
3. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. [J] . Yoshioka H, Hotta K, Kiura K, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2010,第1期

机译：厄洛替尼单药治疗不具有EGFR突变活性的晚期非小细胞肺癌预治疗患者的II期临床试验：冈山肺癌研究小组试验0705。
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. EGFR in Early Non-Small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial. [D] . Lara-Guerra, Humberto. 2011

机译：早期非小细胞肺癌中的EGFR：新辅助试验中酪氨酸激酶抑制作用。
6. Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm phase II study [O] . Shun Lu, Jian-Ying Zhou, Xiao-Min Niu, 2021

机译：Fruquintinib与Gefitinib作为携带EGFR突变的一线治疗具有晚期非小细胞肺癌：单臂II期研究
7. A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705 [O] . Yoshioka Hiroshige, Hotta Katsuyuki, Kiura Katsuyuki, 2010

机译：厄洛替尼单药治疗不具有主动EGFR突变的晚期非小细胞肺癌患者的II期临床试验：冈山肺癌研究小组试验0705

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

著录项

引文网络

相似文献

相关主题

期刊订阅